BillionToOne (BLLN) revenue breakdown
By product, Prenatal is the largest at 91% of fiscal 2025 revenue; Oncology grew fastest, 748% a year over 1 years.
Revenue by product
Fiscal years, as BillionToOne reports them in its 10-K filings; fiscal 2025 total $305M.
| Products | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|
| Prenatal | $69M | $146M | $277M | 91% |
| Oncology | — | $3M | $25M | 8% |
| Clinical trial support and other services | $3M | $4M | $3M | 1% |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for BLLN.
Open BLLN in InvestinglyQuestions
Where does BillionToOne make its money?
In fiscal 2025, by product: Prenatal $277M, Oncology $25M, Clinical trial support and other services $3M.
From BillionToOne's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.